Gaceta medica de Mexico · 2024
Deciphering the prognostic role of serum immunoglobulin G in Guillain-Barré syndrome during intravenous immunoglobulin treatment.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Javier Galnares-Olalde A, Juan López-Hernández C, Verónica Domínguez-Tobón, Edwin Vargas-Cañas S
Аннотация
BACKGROUND: Guillain-Barré syndrome (GBS) is associated with 20% rate of long-term disability. This study explores the pathophysiology of GBS and the mechanism of intravenous immunoglobulin (IVIg).
OBJECTIVE: To investigate whether elevated immunoglobulin G (IgG) levels following IVIg administration are linked to improved recovery of independent walking at 6 months.
MATERIAL AND METHODS: A retro-prospective observational study was conducted. IgG levels were measured before treatment, 7- and 30-days post-initiation. Binary regression analysis assessed the impact of individual factors on prognosis and sequelae. The Kaplan-Meier curve was used to evaluate the proportion of patients who couldn´t walk unaided.
RESULTS: Forty-two patients were included. The mean baseline IgG level was 832.25 mg/dl, increasing to 3053.48 mg/dl at 7 days and decreasing to 1091.72 mg/dl at 30 days. IgG increases at 7 days were categorized into quartiles. Patients with a low increase in IgG levels (< 1945.5 mg/dl) at 7 days exhibited more severe clinical manifestations, including greater needs for invasive mechanical ventilation and increased autonomic dysfunction. Also had poorer walking outcomes at 6 months.
CONCLUSIONS: Lower increase in IgG levels at 7 days post-treatment is associated with a worse prognosis at 6 months, including a reduced likelihood of walking unaided.
OBJECTIVE: To investigate whether elevated immunoglobulin G (IgG) levels following IVIg administration are linked to improved recovery of independent walking at 6 months.
MATERIAL AND METHODS: A retro-prospective observational study was conducted. IgG levels were measured before treatment, 7- and 30-days post-initiation. Binary regression analysis assessed the impact of individual factors on prognosis and sequelae. The Kaplan-Meier curve was used to evaluate the proportion of patients who couldn´t walk unaided.
RESULTS: Forty-two patients were included. The mean baseline IgG level was 832.25 mg/dl, increasing to 3053.48 mg/dl at 7 days and decreasing to 1091.72 mg/dl at 30 days. IgG increases at 7 days were categorized into quartiles. Patients with a low increase in IgG levels (< 1945.5 mg/dl) at 7 days exhibited more severe clinical manifestations, including greater needs for invasive mechanical ventilation and increased autonomic dysfunction. Also had poorer walking outcomes at 6 months.
CONCLUSIONS: Lower increase in IgG levels at 7 days post-treatment is associated with a worse prognosis at 6 months, including a reduced likelihood of walking unaided.